Quantcast

Latest Diabetes management Stories

2014-07-10 23:06:44

All women living with diabetes are encouraged to attend this life-changing weekend. (PRWEB) July 10, 2014 DiabetesSisters is pleased to announce open registration for their upcoming con October 24-25, 2014 at Embassy Suites LAX North in Los Angeles, CA. As the only conference of its kind worldwide for women with diabetes, the event will offer opportunities for women of all ages with all types of diabetes from all walks of life to gain the tools, resources, and connections needed to...

2014-07-10 12:30:43

Business, finance and legal expert brings over forty-five years of experience to LabStyle CAESAREA, Israel, July 10, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced the appointment of Professor Richard B. Stone as an independent member of its Board of Directors. Prof. Stone brings over forty-five years of legal and business experience to LabStyle as an entrepreneur, venture capitalist public,...

2014-07-09 08:29:14

Distribution agreement reached with Viper Medical to market the Dario(TM) Smart Meter, test strips and lancets in the Netherlands CAESAREA, Israel, July 9, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario((TM)) Diabetes Management Solution, announced today that the company is increasing its market reach by entering into an agreement with Viper Medical for exclusive distribution of the Dario(TM) Smart Meter, test strips and lancets in the...

2014-07-09 08:27:32

Trial to Evaluate Efficacy and Safety of LX4211 in Younger Population THE WOODLANDS, Texas, July 9, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. Up to 76 individuals with T1D,...

2014-07-08 23:12:38

Fit4D’s Pathways optimizes the mix between intelligent technology and human touch points to personalize the experience for patients while using claim and pharmacy data to measure health improvements. New York, New York (PRWEB) July 08, 2014 Fit4D© (http://www.fit4d.com) announced today that it is partnering with Healthfirst to deliver an evidence-based diabetes program to Healthfirst’s Spanish speaking members with poorly managed diabetes in New York City. This program will...

2014-07-08 23:02:49

RnRMarketResearch.com adds “World Glucose Self-Testing Markets” and “U.S. Glucose Testing Markets” to its store. The report describes the specific market segments for blood glucose testing and diabetes management in the U.S. and the world market. Dallas, Texas (PRWEB) July 08, 2014 World Glucose Self-Testing Markets The purpose of this World Glucose Self-Testing Markets (http://www.rnrmarketresearch.com/world-glucose-self-testing-markets-market-report.html) report is to provide a...

2014-07-08 00:21:06

Data demonstrates the utility of InSpark's advanced blood glucose pattern recognition technology. CHARLOTTESVILLE, Va., July 7, 2014 /PRNewswire/ -- InSpark Technologies, Inc. announced today that the peer-reviewed Journal of Diabetes Science and Technology has published the paper "Evaluation of the Utility of a Glycemic Pattern Identification System" in its July 2014 issue. The system that is the subject of this paper is being incorporated into InSpark's Vigilant(TM) iPhone-enabled...

2014-07-07 12:28:53

Agents That Can Elicit Greater Weight Loss Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass., July 7, 2014 /PRNewswire/ -- Decision Resources Group finds that Novo Nordisk's fixed-dose combination (FDC) therapy insulin degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold-standard among FDCs used to treat patients with type 2 diabetes. The competitive advantages that this...

2014-07-07 12:24:22

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: MarketVIEW: diabetes vaccineshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_diabetes_vaccines.html Diabetes is a metabolic disorder where the pancreas produces little or no insulin (Type I) OR cells do not respond appropriately to insulin that is produced (Type II). It is estimated that the global prevalence of diabetes is estimated at over 371 million people, a number...

2014-07-03 12:25:46

NEW YORK, July 3, 2014 /PRNewswire/ -- MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The company's lead product - Afrezza inhalation powder - was recently approved by the FDA as a rapid-acting insulin therapy intended to improve glycemic control in adults with type 1 or type 2 diabetes. MannKind was founded by Al Mann for the purpose of developing inhaled insulin as an...


Latest Diabetes management Reference Libraries

Diabetes Care
2012-05-12 21:41:27

Diabetes Care is a peer-reviewed medical journal established in 1978 and published monthly by the American Diabetes Association. It covers research in the following five categories: clinical care/education/nutrition/psychosocial research; epidemiology/health services research; emerging treatments and technologies; pathophysiology/complications; and cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries....

More Articles (1 articles) »
Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related